Chemotherapy — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	199	124	139	545	—	—	1992-08
Malignant Lung Neoplasm	Phase4	Phase 4	35	24	19	101	—	—	1997-01
Malignant Breast Neoplasm	Phase4	Phase 4	20	9	15	50	—	—	1999-01
Non-Hodgkin Lymphoma	Phase4	Phase 4	3	2	4	15	—	—	1997-09
Malignant Liver Neoplasm	Phase4	Phase 4	2	1	1	8	—	—

Curated evidence

Clinical evidence (61)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–50 of 61 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Positive1
Chemotherapy	Acute Myeloid Leukemia

Clinical trials

Trials with this intervention (618)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 618 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05981703	A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	recruiting	Phase 1	337	BeOne MedicinesINDUSTRY	4	Sep 28, 2026	clinicaltrials
NCT07222800	Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer	recruiting

PDGFRA Fusion2
Chemotherapy + ImatinibCombination	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID12566 A previously healthy 2-year-old girl presented with right supraorbital swelling, hepatosplenomegaly, anemia (Hb 8.2 g/dl) and leukocytosis (WBC 19.5 × 109/L) with eosinophilia of 32% and an absolute e… (full text at CIViC) PMID 36589160 · Akiely et al., 2022 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	2	submitted	EID12565 A 10‐year‐old female patient presented with pancytopenia and normal eosinophils and had the diagnosis of B‐lymphoblastic leukemia/lymphoma. FISH identified a CHIC2 deletion, suggestive of FIP1L1::PDG… (full text at CIViC) PMID 39996417 · Nunn et al., 2025 · Open in CIViC	civic

ABL1 Fusion2
Chemotherapy + DasatinibCombination	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	4	submitted	EID11119 An 11 year old female (46,XX) had B-ALL. The patient received a 4-drug induction and end induction day 29 MRD was 5.4%. LDA card was used to analyze the patient and the leukemia was determined to be P… (full text at CIViC) PMID 25207766 · Roberts et al., 2014 · Open in CIViC	civic
Chemotherapy + ImatinibCombination	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	4	submitted	EID12615 A pediatric patient had a hematopathologic diagnosis of B-ALL determined through bone marrow aspirate analysis. The patient had a hemoglobin level of 3 g/dL, severe neutropenia, and a normal platelet … (full text at CIViC) PMID 38749501 · Booth et al., 2025 · Open in CIViC	civic

KRAS Wildtype3
Cetuximab + ChemotherapyCombination	Colorectal Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11057 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	submitted	EID11262 In this open-label, randomized, controlled, phase III trial, 1,198 patients with histologically confirmed adenocarcinoma of the colon or rectum and immunohistochemical evidence of tumour EGFR expressi… (full text at CIViC) PMID 19339720 · Van Cutsem et al., 2009 · Open in CIViC	civic
Chemotherapy + PanitumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	submitted	EID11264 In this randomized, phase III trial, 1,183 patients with previously untreated metastatic adenocarcinoma of the colon or rectum, were randomized 1:1 to receive panitumumab-FOLFOX4 versus FOLFOX4. Panit… (full text at CIViC) PMID 20921465 · Douillard et al., 2010 · Open in CIViC	civic

ERBB2 Amplification2
Chemotherapy + Pembrolizumab + TrastuzumabCombination	Gastroesophageal Junction Adenocarcinoma	Predictive	A	Supports Sensitivity Response	4	submitted	EID11252 In this randomized, double-blind, placebo-controlled, Phase III trial, 264 patients were enrolled with histologically or cytologically confirmed diagnoses of previously untreated, locally advanced, un… (full text at CIViC) PMID 34912120 · Janjigian et al., 2021 · Open in CIViC	civic
Chemotherapy + TrastuzumabCombination	Gastroesophageal Junction Adenocarcinoma	Predictive	A	Supports Sensitivity Response	5	submitted	EID11256 In this phase 3, open-label, randomized controlled trial, 594 patients (584 in the primary analysis) with HER2-positive amplification or overexpression gastric or gastroesophageal junction adenocarcin… (full text at CIViC) PMID 20728210 · Bang et al., 2010 · Open in CIViC	civic

KRAS Mutation2
Bevacizumab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID1139 Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P… (full text at CIViC) PMID 23828442 · Petrelli et al., 2013 · Open in CIViC	civic
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID3704 This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codo… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic